摘要
托法替尼是第一个被批准用于治疗类风湿关节炎(RA)的Janus激酶(JAK)抑制剂。该药物口服可降低JAK1、JAK2和JAK3的活性,在Ⅲ期临床试验中被证明可提供与注射生物DMARD(bDMARD)相似疗效的替代药物。截至目前,其他更具选择性的JAK抑制剂也获得批准上市,临床治疗需要了解这些化合物的相对安全性。ORALSURV是一项FDA授权的上市后ⅢB-Ⅳ期临床研究,重点是观察接受托法替尼或bDMARD治疗患者的主要不良事件发生率。JAK抑制剂安全性的相关性研究结果显示,静脉血栓栓塞可能是与JAK抑制剂相关的真正风险。
Tofacitinib was the first Janus kinase(JAK)inhibitor to be approved for the treatment of rheumatoid arthritis(RA).This medication,which diminishes the activity of JAK1,JAK2 and JAK3,was proven in phase III trials to offer an alternative of similar efficacy to injectable biologic DMARDs(bDMARDs).Up to now,other more selective JAK inhibitor have been approved.Hence it is of significance to understand the relative safety of these compounds.ORALSURV was post-marketing phase IIIb-IV study.The trial's primary end points were adverse events for Tofacitinib and bDMARDs.This review summarizes the results relative to JAK inhibitor and the new data indicated that venous thromboembolism might be a true risk related to JAK inhibition.
作者
闫沁远
YAN Qin-yuan(Hubei Polytechnic Institute,Xiaogan,Hubei 432000,China)
出处
《湖北职业技术学院学报》
2023年第4期105-109,共5页
Journal of Hubei Polytechnic Institute
